Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer
J McLaughlin, G Han, KA Schalper… - JAMA …, 2016 - jamanetwork.com
Importance Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell
death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable
clinical responses in patients with non–small-cell lung cancer (NSCLC). However, current
assays for the prognostic and/or predictive role of tumor PD-L1 expression are not
standardized with respect to either quantity or distribution of expression. Objective To
demonstrate PD-L1 protein distribution in NSCLC tumors using both conventional …
death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable
clinical responses in patients with non–small-cell lung cancer (NSCLC). However, current
assays for the prognostic and/or predictive role of tumor PD-L1 expression are not
standardized with respect to either quantity or distribution of expression. Objective To
demonstrate PD-L1 protein distribution in NSCLC tumors using both conventional …